Elan Corp. (ELN) Misses Street's Q2 View
More News related to ELN
- Elan to Present at Lazard Capital Markets 6th Annual Healthcare Conference
- Elan Corporation Plc Announces Expiration of Tender Offer for 73/4% Senior Fixed Rate Notes Due 2011
- UBS Downgrades Elan (ELN) to Neutral
- Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Reduces Rates of Hospitalization in Patients with Moderate-to-Severe Crohn's Disease
- Trading Outlook for Elan Corp. Plc. Issued by InvestorSoup.com
More News related to Earnings
- Nexstar Broadcasting (NXST) Posts Q3 Loss of $0.65, Better Y/Y
- Allot Communications (ALLT) Posts Q3 EPS of $0.01, Tops Views by 3c
- Flowers Foods (FLO) Posts Q3 EPS of $0.34, In-Line with Estimates
- Pan American Silver (PAAS) Misses Q3 EPS Views by 1c
- Communications Systems (JCS) Reports Year-Over-Year Decline in Q3 Earnings
Elan Corporation, plc (NYSE: ELN) reports a Q2 loss of $0.50, versus the analyst estimate of ($0.13). Revenues for the quarter were $245.6 million, versus the consensus of $249.49 million.
Elan Corporation, plc operates as a neuroscience-based biotechnology company primarily in Ireland and the United States.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
